Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up

Revista Brasileira de Psiquiatria

Volumn 29, Issue 4, 2007, Pages 346-349

  Attux, Cecília ^a,b   Quintana, Maria Inês ^a   Chaves, Ana Cristina ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Rua Borges Lagoa   (Brazil)

Author keywords

Metabolic syndrome X; Obesity; Primary treatment; Psychosis; Weight gain

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; CHLORPROMAZINE; CHOLESTEROL; SULPIRIDE; THIORIDAZINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEIGHT; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATIENT MONITORING; PHYSICAL ACTIVITY; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; WEIGHT; WEIGHT GAIN; BODY MASS; BODY WEIGHT; BRAZIL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; NONPARAMETRIC TEST; OBESITY; SEX DIFFERENCE; TIME; CONTROLLED STUDY; DIABETES MELLITUS; LABORATORY TEST; METABOLIC PARAMETERS; SIDE EFFECT; WAIST CIRCUMFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; BODY WEIGHT; BRAZIL; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLIC SYNDROME X; OBESITY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEX FACTORS; STATISTICS, NONPARAMETRIC; TIME FACTORS; WEIGHT GAIN;

EID: 38349180996     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-44462006005000061     Document Type: Article

References (27)

1. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28(Suppl 1):83-96.
2. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60(4):215-20.
3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-96.
4. de Sena EP, Sampaio AS, Quarantin LC, Oliveira IR. Diabetes mellitus e antipsicóticos atípicos. Rev Bras Psiquiatr. 2003;25(4):253-7.
5. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159(4):561-6.
6. Khunti K, Davies M. Metabolic syndrome. BMJ. 2005;331(7526):1153- 4.
7. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA. The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005;80(1):9-18.
8. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006;95(3):136-47.
9. Addington J, Mansley C, Addington D. Weight gain in first-episode patients. Can J Psychiatry. 2003;48(4):272-6.
10. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-43.
11. Sistema de Vigilância Alimentar e Nutricional (SISVAN). Manual de Orientações Básicas para a Coleta, Processamento, Análise de Dados e Informação em Serviços de Saúde (2004). [citado 15 fev 2007] Disponível em: www.saude.gov.br/alimentacao].
12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
13. Leitao-Azevedo CL, Guimaraes R, Abreu MG, Gama CS, Lobato MI, Belmonte-de-Abreu PA. Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics. Rev Bras Psiquiatr. 2006;28(4):301-4.
14. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naïve patients with schizophrenia. Life Sci. 2004;74(16):1999-2008.
15. Sacks FM. Metabolic syndrome: epidemiology and consequences. J Clin Psychiatry. 2004;65(Suppl 18):3-12.
16. Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry. 2005;162(1):118-23.
17. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 2004;161(8):1324-33.
18. Chaves AC, Seeman MV. Sex selection bias in schizophrenia antipsychotic trials. J Clin Psychopharmacology. 2006;26(5):489-94.
19. Barbui C, Nose M, Bindman J, Schene A, Becker T, Mazzi MA, Kikkert M, Camara J, Born A, Tansella M. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol. 2005;25(6):521-6.
20. Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf. 2006;29(7):587-98.
21. Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry. 1999;60(Suppl 21):31-6.
22. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand. 2003;108(5):324-32.
23. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry. 2004;65(4):471-7.
24. Attux C, Araújo C, Roma A, Mateus M, Campagna L, Canguçu D, Bressan R. Brazilian Wellness Program: results from first year. Int J Neuropsychophamacol. 2006;9(Suppl. 1):S156.
25. Lieberman JA 3rd. Metabolic changes associated with antipsychotic use. Prim Care Companion J Clin Psychiatry. 2004;6(Suppl. 2):8-13.
26. Reis AF. Antipsychotic drugs and metabolic syndrome: can we prevent it? Rev Bras Psiquiatr. 2007;29(1):9-10.
27. Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs. 2005;65(8):1113-38.